|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnson DH, Schiller JH and Bunn PA Jr:
Recent clinical advances in lung cancer management. J Clin Oncol.
32:973–982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/American thoracic society/European respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhan C, Yan L, Wang L, Sun Y, Wang X, Lin
Z, Zhang Y, Shi Y, Jiang W and Wang Q: Identification of
immunohistochemical markers for distinguishing lung adenocarcinoma
from squamous cell carcinoma. J Thorac Dis. 7:1398–1405.
2015.PubMed/NCBI
|
|
7
|
Kishimoto T, Akira S, Narazaki M and Taga
T: Interleukin-6 family of cytokines and gp130. Blood.
86:1243–1254. 1995.PubMed/NCBI
|
|
8
|
Hodge DR, Hurt EM and Farrar WL: The role
of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer.
41:2502–2512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haura EB, Livingston S and Coppola D:
Autocrine interleukin-6/interleukin-6 receptor stimulation in
non-small-cell lung cancer. Clin Lung Cancer. 7:273–275. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yanagawa H, Sone S, Takahashi Y, Haku T,
Yano S, Shinohara T and Ogura T: Serum levels of interleukin 6 in
patients with lung cancer. Br J Cancer. 71:1095–1098. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Songür N, Kuru B, Kalkan F, Ozdilekcan C,
Cakmak H and Hizel N: Serum interleukin-6 levels correlate with
malnutrition and survival in patients with advanced non-small cell
lung cancer. Tumori. 90:196–200. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai
YH, Chen YM, Huang MS, Chen HL, Li YJ, Yang PC, et al: Circulating
interleukin-6 level is a prognostic marker for survival in advanced
nonsmall cell lung cancer patients treated with chemotherapy. Int J
Cancer. 132:1977–1985. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seike T, Fujita K, Yamakawa Y, Kido MA,
Takiguchi S, Teramoto N, Iguchi H and Noda M: Interaction between
lung cancer cells and astrocytes via specific inflammatory
cytokines in the microenvironment of brain metastasis. Clin Exp
Metastasis. 28:13–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Noda M, Yamakawa Y, Matsunaga N, Naoe S,
Jodoi T, Yamafuji M, Akimoto N, Teramoto N, Fujita K, Ohdo S and
Iguchi H: IL-6 receptor is a possible target against growth of
metastasized lung tumor cells in the brain. Int J Mol Sci.
14:515–526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yi H, Cho HJ, Cho SM, Jo K, Park JA, Kim
NH, Amidon GL, Kim JS and Shin HC: Blockade of interleukin-6
receptor suppresses the proliferation of H460 lung cancer stem
cells. Int J Oncol. 41:310–316. 2012.PubMed/NCBI
|
|
16
|
Kim NH, Kim SK, Kim DS, Zhang D, Park JA,
Yi H, Kim JS and Shin HC: Anti-proliferative action of
IL-6R-targeted antibody tocilizumab for non-small cell lung cancer
cells. Oncol Lett. 9:2283–2288. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ando K, Takahashi F, Motojima S, Nakashima
K, Kaneko N, Hoshi K and Takahashi K: Possible role for
tocilizumab, an anti-interleukin-6 receptor antibody, in treating
cancer cachexia. J Clin Oncol. 31:e69–e72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ando K, Takahashi F, Kato M, Kaneko N, Doi
T, Ohe Y, Koizumi F, Nishio K and Takahashi K: Tocilizumab, a
proposed therapy for the cachexia of Interleukin6-expressing lung
cancer. PLoS One. 9:e1024362014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Budczies J, Klauschen F, Sinn BV, Győrffy
B, Schmitt WD, Darb-Esfahani S and Denkert C: Cutoff Finder: A
comprehensive and straightforward Web application enabling rapid
biomarker cutoff optimization. PLoS One. 7:e518622012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu CQ, Ding K, Strumpf D, Weir BA,
Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et
al: Prognostic and predictive gene signature for adjuvant
chemotherapy in resected non-small-cell lung cancer. J Clin Oncol.
28:4417–4424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rousseaux S, Debernardi A, Jacquiau B,
Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY,
Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and
placental genes identifies aggressive metastasis-prone lung
cancers. Sci Transl Med. 5:186ra662013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Botling J, Edlund K, Lohr M, Hellwig B,
Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, et
al: Biomarker discovery in non-small cell lung cancer: Integrating
gene expression profiling, meta-analysis, and tissue microarray
validation. Clin Cancer Res. 19:194–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang H, Xiao G, Behrens C, Schiller J,
Allen J, Chow CW, Suraokar M, Corvalan A, Mao J, White MA, et al: A
12-gene set predicts survival benefits from adjuvant chemotherapy
in non-small cell lung cancer patients. Clin Cancer Res.
19:1577–1586. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Der SD, Sykes J, Pintilie M, Zhu CQ,
Strumpf D, Liu N, Jurisica I, Shepherd FA and Tsao MS: Validation
of a histology-independent prognostic gene signature for
early-stage, non-small-cell lung cancer including stage IA
patients. J Thorac Oncol. 9:59–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Director's Challenge Consortium for the
Molecular Classification of Lung Adenocarcinoma, . Shedden K,
Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S,
Jurisica I, Giordano TJ, et al: Gene expression-based survival
prediction in lung adenocarcinoma: A multi-site, blinded validation
study. Nat Med. 14:822–827. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Beer DG, Kardia SL, Huang CC, Giordano TJ,
Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al:
Gene-expression profiles predict survival of patients with lung
adenocarcinoma. Nat Med. 8:816–824. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu H and Jove R: The STATs of cancer-new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han X, Li F, Fang Z, Gao Y, Li F, Fang R,
Yao S, Sun Y, Li L, Zhang W, et al: Transdifferentiation of lung
adenocarcinoma in mice with Lkb1 deficiency to squamous cell
carcinoma. Nat Commun. 5:32612014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sutherland KD and Berns A: Cell of origin
of lung cancer. Mol Oncol. 4:397–403. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hassan KA, Chen G, Kalemkerian GP, Wicha
MS and Beer DG: An embryonic stem cell-like signature identifies
poorly differentiated lung adenocarcinoma but not squamous cell
carcinoma. Clin Cancer Res. 15:6386–6390. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li P, Zhang L, Yu X, Tong R, Di X, Mao Y,
Gao Y, Zhang K, Feng L and Cheng S: Proliferation genes in lung
development associated with the prognosis of lung adenocarcinoma
but not squamous cell carcinoma. Cancer Sci. 109:308–316. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Montero-Julian FA: The soluble IL-6
receptors: Serum levels and biological function. Cell Mol Biol
(Noisy-le-grand). 47:583–597. 2001.PubMed/NCBI
|
|
34
|
Brooks GD, McLeod L, Alhayyani S, Miller
A, Russell PA, Ferlin W, Rose-John S, Ruwanpura S and Jenkins BJ:
IL6 trans-signaling promotes KRAS-driven lung carcinogenesis.
Cancer Res. 76:866–876. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Balabko L, Andreev K, Burmann N, Schubert
M, Mathews M, Trufa DI, Reppert S, Rau T, Schicht M, Sirbu H, et
al: Increased expression of the Th17-IL-6R/pSTAT3/BATF/RorγT-axis
in the tumoural region of adenocarcinoma as compared to squamous
cell carcinoma of the lung. Sci Rep. 4:73962014. View Article : Google Scholar : PubMed/NCBI
|
